image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IS
$ 11.73
-2.82 %
$ 3.54 B
Market Cap
-4.55
P/E
1. INTRINSIC VALUE

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.[ Read More ]

The intrinsic value of one ALVO stock under the base case scenario is HIDDEN Compared to the current market price of 11.7 USD, Alvotech is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALVO

image
FINANCIALS
91.4 M REVENUE
10.12%
-355 M OPERATING INCOME
-2.43%
-552 M NET INCOME
-7.43%
-312 M OPERATING CASH FLOW
0.07%
-46.3 M INVESTING CASH FLOW
27.07%
301 M FINANCING CASH FLOW
-29.09%
199 M REVENUE
1498.98%
91.9 M OPERATING INCOME
226.05%
65.2 M NET INCOME
129.82%
-50.6 M OPERATING CASH FLOW
32.90%
-7.09 M INVESTING CASH FLOW
-103.71%
4 M FINANCING CASH FLOW
-97.00%
Balance Sheet Decomposition Alvotech
image
Current Assets 195 M
Cash & Short-Term Investments 11.2 M
Receivables 87.2 M
Other Current Assets 96.5 M
Non-Current Assets 755 M
Long-Term Investments 18.5 M
PP&E 357 M
Other Non-Current Assets 380 M
Current Liabilities 261 M
Accounts Payable 80.6 M
Short-Term Debt 47.7 M
Other Current Liabilities 133 M
Non-Current Liabilities 1.62 B
Long-Term Debt 1.03 B
Other Non-Current Liabilities 594 M
EFFICIENCY
Earnings Waterfall Alvotech
image
Revenue 91.4 M
Cost Of Revenue 161 M
Gross Profit -69.4 M
Operating Expenses 285 M
Operating Income -355 M
Other Expenses 197 M
Net Income -552 M
RATIOS
-75.93% GROSS MARGIN
-75.93%
-388.11% OPERATING MARGIN
-388.11%
-603.42% NET MARGIN
-603.42%
59.17% ROE
59.17%
-58.07% ROA
-58.07%
-1086.99% ROIC
-1086.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alvotech
image
Net Income -552 M
Depreciation & Amortization 24.2 M
Capital Expenditures -46.5 M
Stock-Based Compensation 18 M
Change in Working Capital 26.3 M
Others 306 M
Free Cash Flow -359 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alvotech
image
Wall Street analysts predict an average 1-year price target for ALVO of $19.7 , with forecasts ranging from a low of $17 to a high of $22 .
ALVO Lowest Price Target Wall Street Target
17 USD 44.93%
ALVO Average Price Target Wall Street Target
19.7 USD 67.66%
ALVO Highest Price Target Wall Street Target
22 USD 87.55%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Alvotech
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Alvotech (ALVO) Q3 2024 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Chairman and Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategy Officer Conference Call Participants Balaji Prasad - Barclays Niall Alexander - Deutsche Bank Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech's Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 days ago
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates Alvotech (ALVO) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.82 per share a year ago. zacks.com - 3 days ago
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi's 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore's HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore's HealthCONx Conference on Thursday, December 5, 2024 starting at 12:55 ET (17:55 GMT). globenewswire.com - 1 week ago
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi's 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore's HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore's HealthCONx Conference on Thursday, December 5, 2024 starting at 12:55 ET (17:55 GMT). globenewswire.com - 1 week ago
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab),  a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025. "This is a welcome milestone for us, our partners, patients and caregivers, as we take one step closer to being able to offer access to biosimilar Simponi®," said Joseph McClellan, Chief Scientific Officer of Alvotech. “We believe having the capability and know-how inhouse to utilize a host cell line and process also used to manufacture the reference biologic, has given us an important head start in developing a biosimilar candidate to Simponi®." “The EMA's acceptance of the application for AVT05 represents a significant step forward in expanding treatment options for patients with chronic inflammatory diseases across Europe,” said Nick Warwick, Chief Medical Officer of Advanz Pharma. “We are committed to improving patient access to high-quality biologic medicines.” Alvotech and Advanz Pharma first announced in February 2023 that the companies had entered into a commercialization agreement, for AVT23, a proposed biosimilar to Xolair® (omalizumab). In May this year, the partners announced an expansion of the strategic partnership, to include five additional biosimilar candidates being developed by Alvotech, AVT05, AVT16 a proposed biosimilar to Entyvio® (vedolizumab) and three additional early-stage biosimilar candidates which remain undisclosed. In April 2024 Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between AVT05 and Simponi® in patients with moderate to severe rheumatoid arthritis. In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants. globenewswire.com - 1 week ago
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025. globenewswire.com - 1 week ago
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. globenewswire.com - 3 weeks ago
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. globenewswire.com - 3 weeks ago
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025. globenewswire.com - 3 weeks ago
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025. globenewswire.com - 3 weeks ago
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025. globenewswire.com - 3 weeks ago
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab). globenewswire.com - 1 month ago
8. Profile Summary

Alvotech ALVO

image
COUNTRY IS
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 3.54 B
Dividend Yield 0.00%
Description Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Contact Saemundargata 15-19, Reykjavik, 102 https://www.alvotech.com
IPO Date June 16, 2022
Employees 999
Officers Ms. Jenny Sif Steingrimsdottir Vice President of People & Culture Mr. Anil Okay Chief Commercial Officer Mr. Joseph E. McClellan Chief Scientific Officer Mr. Ming Li Chief Strategy Officer Mr. Joel Morales Chief Financial Officer Ms. Tanya Zharov General Counsel Ms. Christina Siniscalchi Chief Quality Officer Mr. Faysal Kalmoua Chief Operating Officer & Director Mr. Giedrius Zunda Chief Technical Officer Mr. Robert Wessman Chief Executive Officer, Founder & Executive Chairman